KORU Medical Systems近日宣布，其Freedomedge®输液系统已获得美国食品药品监督管理局（FDA）的510(K)许可，可用于输注Rystiggo®（Rozanolixizumab-Noli）。这一批准标志着Freedomedge®输液系统的标签得到重要扩展，为其在特定药物输送领域的应用开辟了新途径。
此次许可不仅强化了KORU Medical Systems在医疗设备领域的创新地位，也为患者提供了更高效、便捷的治疗方案。公司表示，这一进展将进一步提升其在专业输液解决方案市场的竞争力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.